nintedanib
Multi-kinase inhibitor targeting VEGFR, FGFR, and PDGFR pathways
Liu R, Zhi L, Liang Y et al.
Bao H, Deng C, Luo X et al.
Ruenwilai P, Tajarernmuang P, Chattipakorn SC et al.
Zhou X, Zhao L, Ma W et al.
Lee T, Lim YJ, Li AY et al.
This drug has been validated in the following preclinical models: